English to Chinese: 沙门氏菌疫苗M735 General field: Science | |
Source text - English The aim of the study was to test for the protection conferred by two formulations of the Salmonella vaccine M735 against an oral Salmonella Enteritidis (SE) challenge in laying hens at the end of the laying period (52 weeks age). The efficacy was assessed through fecal re-excretion of the challenge strain.
During their initial rearing period, the birds received a standard vaccination programme, as would be used in the field. In addition, 2 groups of pullets were immunised by intramuscular injections of M735 vaccine at 6 and 16 weeks of age. At D0 of the study, when they were 52 weeks of age, the hens were challenged by crop-gavage with ca.8 log10 colony forming units (CFU) per bird of SE16530, a nalidixate-resistant derivative of a PT4 field isolate. The SE serology status of each bird was checked before the challenge.
| Translation - Chinese 该研究目的为测试二种配方的沙门氏菌疫苗M735对口服接种肠炎沙门氏菌的产蛋末期蛋鸡(52周)的保护作用。疫苗的有效性通过检测粪便排泄物中的攻击菌株来评价。
在饲养初期,蛋鸡接受和鸡场相同的标准疫苗方案。除此之外,在第6周龄和第16周龄,2组青年鸡通过肌肉注射M735疫苗获得免疫。在实验的第0天,即52周龄时通过嗉囊喂养法进行肠炎沙门氏菌株SE16530(10^8CFU/只)攻毒。SE16530为PT4野生分离株的一种耐萘啶酸衍生物。在攻毒前每只蛋鸡的肠炎沙门氏菌血清学均已被检测。
|
Chinese to English: 子宫肌瘤III期多中心随机对照临床试验 General field: Medical | |
Source text - Chinese 通过两项III期多中心随机对照临床试验来评价药物的有效性。两项试验的受试者皆为子宫肌瘤患者,用药周期皆为3个月(84天)。研究1为一个多中心随机阳性对照试验,阳性对照药为醋酸亮丙瑞林,每28天皮下注射一次。研究2为一个多中心随机双盲安慰剂对照试验。两个研究的主要疗效指标为:用药后子宫最大肌瘤体积变化率;次要疗效指标为:用药后患者贫血状况的改善,包括红细胞计数、血红蛋白和红细胞比积的变化;用药前后临床症状的改善,包括月经量、压迫症状、痛经和非经期下腹痛的变化。 | Translation - English The efficacy of Leuprorelin Acetate in treating uterine leiomyomas was assessed by conducting two independent, phase III, randomized and multicentre controlled clinical trials in uterine leiomyomas patients during a 3-month (84-day) period. Clinical trial 1 was a randomized, positive drug control, multicentre trial. The uterine leiomyomas patients received the positive control drug Leuprorelin Acetate subcutaneously (q28 d). Clinical trial 2 was a randomized, double-blind, placebo-controlled, multicentre trial. The main therapeutic effect index was the maximum reduction rate in fibroid volume after drug administration. The secondary therapeutic effect indexes were alleviation of anemia after drug administration including changes of RBC count, hemoglobin concentration and hematocrit, as well as alleviation of clinical symptoms including changes of menstrual blood volume, pressure and abdominal pain during and in between menstrual periods. |